<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00541658</url>
  </required_header>
  <id_info>
    <org_study_id>2007008</org_study_id>
    <nct_id>NCT00541658</nct_id>
  </id_info>
  <brief_title>A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis</brief_title>
  <official_title>A Non-inferiority Comparison of 35 mg Delayed-release Risedronate, Given Once-weekly Either Before or After Breakfast, &amp; 5 mg Immediate-release Risedronate, Given Once-daily Before Breakfast, in the Treatment of Postmenopausal Osteoporosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing
      regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The comparator arms of this risedronate study are 35 mg delayed release given weekly and 5 mg
      immediate release given daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Week 52 / Endpoint, ITT Population</measure>
    <time_frame>52 weeks / Endpoint</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Lumbar Spine BMD for Combined 35 mg Delayed-Release Weekly Treatment Group, Week 52 / Endpoint, ITT Population</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Lumbar Spine BMD, Week 26, ITT Population</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Lumbar Spine BMD, Week 52, ITT Population</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Lumbar Spine BMD at Week 104, ITT Population</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Lumbar Spine BMD at Week 104 / Endpoint, ITT Population</measure>
    <time_frame>Week 104 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD), Week 52, ITT Population</measure>
    <time_frame>Week 52</time_frame>
    <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD) at Week 52 / Endpoint, ITT Population</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
    <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD) at Week 104, ITT Population</measure>
    <time_frame>Week 52</time_frame>
    <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD) at Week 104 / Endpoint, ITT Population</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
    <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Proximal Femur BMD, Week 26, ITT Population</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Proximal Femur BMD, Week 52, ITT Population</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Total Proximal Femur BMD, Week 52 / Endpoint, ITT Population</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Total Proximal Femur BMD, Week 104, ITT Population</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Total Proximal Femur BMD, Week 104 / Endpoint, ITT Population</measure>
    <time_frame>Week 104 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck BMD, Week 26, ITT Population</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck BMD, Week 52, ITT Population</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck BMD, Week 52 / Endpoint, ITT Population</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck BMD, Week 104, ITT Population</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck BMD, Week 104 / Endpoint, ITT Population</measure>
    <time_frame>Week 104 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Greater Trochanter BMD, Week 26, ITT Population</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Greater Trochanter BMD, Week 52, ITT Population</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Greater Trochanter BMD, Week 52 / Endpoint</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Greater Trochanter BMD, Week 104, ITT Population</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Greater Trochanter BMD, Week 104 / Endpoint</measure>
    <time_frame>Week 104 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Urine Type-I Collagen N-telopeptide/ Creatinine (NTX/Cr), Week 13, ITT Population</measure>
    <time_frame>Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 26, ITT Population</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 52, ITT Population</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 52 / Endpoint, ITT Population</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 104, ITT Population</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 104 / Endpoint, ITT Population</measure>
    <time_frame>Week 104 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Serum Type-I Collagen C-telopeptide (CTX), Week 13, ITT Population</measure>
    <time_frame>Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Serum Type-I Collagen C-telopeptide (CTX), Week 26, ITT Population</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 52, ITT Population</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 52 / Endpoint, ITT Population</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 104, ITT Population</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 104 / Endpoint, ITT Population</measure>
    <time_frame>Week 104 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 13, ITT Population</measure>
    <time_frame>Week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 26, ITT Population</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 52, ITT Population</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 52 / Endpoint, ITT Population</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 104, ITT Population</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 104 / Endpoint, ITT Population</measure>
    <time_frame>Week 104 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One New Fractured Vertebra, Week 52</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One New Fractured Vertebra, Week 52 / Endpoint, ITT Population</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One New Fractured Vertebra, Week 104, ITT Population</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One New Fractured Vertebra, Week 104 / Endpoint, ITT Population</measure>
    <time_frame>Week 104 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With No New Fractured Vertebra, Week 52</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With No New Fractured Vertebra, Week 52 / Endpoint</measure>
    <time_frame>Week 52 / Endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With No New Fractured Vertebra, Week 104</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With No New Fractured Vertebra, Week 104 / Endpoint</measure>
    <time_frame>Week 104 / Endpoint</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">923</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>5 mg Before Breakfast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>35 mg After Breakfast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 mg / Delayed-release Risedronate (Immediately Following Breakfast)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>35 mg Before Breakfast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily</description>
    <arm_group_label>5 mg Before Breakfast</arm_group_label>
    <other_name>IRBB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly</description>
    <arm_group_label>35 mg After Breakfast</arm_group_label>
    <other_name>DRFB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly</description>
    <arm_group_label>35 mg Before Breakfast</arm_group_label>
    <other_name>DRBB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female: 50 years of age or older

          -  &gt;5 years since last menses natural or surgical

          -  have lumbar spine or total hip BMD more that 2.5 SD below the young adult mean, or
             have lumbar spine or total hip BMD more than 2.0 SD below the young adult female mean
             value and also have at least one prevalent vertebral body fracture

        Exclusion Criteria:

          -  history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia

          -  BMI &gt;32 kg/m

          -  use of medications within 3 months of starting study drug that impact bone metabolism
             such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and
             parathyroid hormone

          -  hypocalcemia or hypercalcemia of any cause

          -  markedly abnormal clinical laboratory measurements that are assessed as clinically
             significant by the investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Balske, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Procter and Gamble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Diepenbeek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St-Eustache</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orleans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vandoeuvre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koranyi Sandor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2007</study_first_posted>
  <results_first_submitted>April 13, 2011</results_first_submitted>
  <results_first_submitted_qc>May 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 21, 2011</results_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>923 women with PMO at 43 sites in 8 countries across North America, South America, and the European Union. Patients were randomized within a site to 1 of 3 treatment groups (35 mg delayed-release Risedronate, given once-weekly before/after breakfast, and 5 mg immediate-release Risedronate, administered once-daily before breakfast) in a 1:1:1 ratio.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>5 mg Before Breakfast</title>
          <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
        </group>
        <group group_id="P2">
          <title>35 mg After Breakfast</title>
          <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
        </group>
        <group group_id="P3">
          <title>35 mg Before Breakfast</title>
          <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="307"/>
                <participants group_id="P3" count="308"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>ITT Population</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="307"/>
                <participants group_id="P3" count="308"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="248"/>
                <participants group_id="P2" count="234"/>
                <participants group_id="P3" count="240"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Took No Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>5 mg Before Breakfast</title>
          <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
        </group>
        <group group_id="B2">
          <title>35 mg After Breakfast</title>
          <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
        </group>
        <group group_id="B3">
          <title>35 mg Before Breakfast</title>
          <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="308"/>
            <count group_id="B2" value="307"/>
            <count group_id="B3" value="308"/>
            <count group_id="B4" value="923"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>ITT Population</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="7.4"/>
                    <measurement group_id="B2" value="65.8" spread="7.4"/>
                    <measurement group_id="B3" value="66.0" spread="7.5"/>
                    <measurement group_id="B4" value="65.7" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>ITT Population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 65 and &lt; 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; = 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>ITT Population</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="307"/>
                    <measurement group_id="B2" value="307"/>
                    <measurement group_id="B3" value="308"/>
                    <measurement group_id="B4" value="922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Week 52 / Endpoint, ITT Population</title>
        <time_frame>52 weeks / Endpoint</time_frame>
        <population>Intention-to-Treat (ITT) Population. Last Observation Carried Forward (LOCF) at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Lumbar Spine Bone Mineral Density (BMD) at Week 52 / Endpoint, ITT Population</title>
          <population>Intention-to-Treat (ITT) Population. Last Observation Carried Forward (LOCF) at Week 52.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.069" lower_limit="2.664" upper_limit="3.474"/>
                    <measurement group_id="O2" value="3.302" lower_limit="2.890" upper_limit="3.715"/>
                    <measurement group_id="O3" value="3.365" lower_limit="2.961" upper_limit="3.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.233</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.812</ci_lower_limit>
            <ci_upper_limit>0.345</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.296</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.869</ci_lower_limit>
            <ci_upper_limit>0.277</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Lumbar Spine BMD for Combined 35 mg Delayed-Release Weekly Treatment Group, Week 52 / Endpoint, ITT Population</title>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>35 mg group combined delayed-relase following breakfast (DRFB) group with delayed-relase before breakfast (DRBB) group and compared with 5 mg immediate-release before breakfast (IRBB) group. ITT Population. Last Observation Carried Forward at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg IRBB</title>
            <description>5 mg immediate-release risedronate tablet daily, at least 30 minutes before breakfast for two years</description>
          </group>
          <group group_id="O2">
            <title>35 mg DRFB + DRBB</title>
            <description>Combined two arms - 35 mg delayed-release following breakfast (DRFB) with 35 mg delayed-relase before breakfast (DRBB)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Lumbar Spine BMD for Combined 35 mg Delayed-Release Weekly Treatment Group, Week 52 / Endpoint, ITT Population</title>
          <population>35 mg group combined delayed-relase following breakfast (DRFB) group with delayed-relase before breakfast (DRBB) group and compared with 5 mg immediate-release before breakfast (IRBB) group. ITT Population. Last Observation Carried Forward at Week 52.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="532"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.069" lower_limit="2.664" upper_limit="3.474"/>
                    <measurement group_id="O2" value="3.334" lower_limit="3.046" upper_limit="3.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.2955</p_value>
            <method>ANOVA</method>
            <method_desc>Fixed effects for treatment, pooled center and anticoagulant used.</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.265</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.763</ci_lower_limit>
            <ci_upper_limit>0.232</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Lumbar Spine BMD, Week 26, ITT Population</title>
        <time_frame>Week 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Lumbar Spine BMD, Week 26, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.685" lower_limit="2.305" upper_limit="3.066"/>
                    <measurement group_id="O2" value="2.816" lower_limit="2.429" upper_limit="3.203"/>
                    <measurement group_id="O3" value="2.529" lower_limit="2.148" upper_limit="2.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.131</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.674</ci_lower_limit>
            <ci_upper_limit>0.412</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.156</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.382</ci_lower_limit>
            <ci_upper_limit>0.695</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Lumbar Spine BMD, Week 52, ITT Population</title>
        <time_frame>Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Lumbar Spine BMD, Week 52, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.035" lower_limit="2.627" upper_limit="3.443"/>
                    <measurement group_id="O2" value="3.293" lower_limit="2.883" upper_limit="3.702"/>
                    <measurement group_id="O3" value="3.357" lower_limit="2.949" upper_limit="3.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.258</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.836</ci_lower_limit>
            <ci_upper_limit>0.321</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.322</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.900</ci_lower_limit>
            <ci_upper_limit>0.256</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Lumbar Spine BMD at Week 104, ITT Population</title>
        <time_frame>Week 104</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Lumbar Spine BMD at Week 104, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.352" lower_limit="3.829" upper_limit="4.874"/>
                    <measurement group_id="O2" value="5.506" lower_limit="4.971" upper_limit="6.040"/>
                    <measurement group_id="O3" value="5.396" lower_limit="4.865" upper_limit="5.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.154</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.903</ci_lower_limit>
            <ci_upper_limit>-0.405</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.789</ci_lower_limit>
            <ci_upper_limit>-0.299</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Lumbar Spine BMD at Week 104 / Endpoint, ITT Population</title>
        <time_frame>Week 104 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Lumbar Spine BMD at Week 104 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.147" lower_limit="3.653" upper_limit="4.640"/>
                    <measurement group_id="O2" value="5.205" lower_limit="4.703" upper_limit="5.707"/>
                    <measurement group_id="O3" value="5.068" lower_limit="4.574" upper_limit="5.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.059</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.762</ci_lower_limit>
            <ci_upper_limit>-0.355</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.922</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.620</ci_lower_limit>
            <ci_upper_limit>-0.223</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD), Week 52, ITT Population</title>
        <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD), Week 52, ITT Population</title>
          <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
          <population>ITT Population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.0524</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.1207</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD) at Week 52 / Endpoint, ITT Population</title>
        <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD) at Week 52 / Endpoint, ITT Population</title>
          <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
          <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5"/>
                    <measurement group_id="O2" value="87.4"/>
                    <measurement group_id="O3" value="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.0729</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.1639</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD) at Week 104, ITT Population</title>
        <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
        <time_frame>Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD) at Week 104, ITT Population</title>
          <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
          <population>ITT Population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="89.2"/>
                    <measurement group_id="O3" value="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.0476</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.0014</p_value>
            <method>ANOVA</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD) at Week 104 / Endpoint, ITT Population</title>
        <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Responders to Treatment (&gt;0% Change From Baseline in Lumbar Spine BMD) at Week 104 / Endpoint, ITT Population</title>
          <description>Responder = a patient showing a positive change (&gt;0 g/cm2) in lumbar spine BMD from baseline to the timepoint.</description>
          <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8"/>
                    <measurement group_id="O2" value="87.9"/>
                    <measurement group_id="O3" value="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.0547</p_value>
            <method>ANOVA</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.0066</p_value>
            <method>ANOVA</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Proximal Femur BMD, Week 26, ITT Population</title>
        <time_frame>Week 26</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Proximal Femur BMD, Week 26, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.613" lower_limit="1.354" upper_limit="1.872"/>
                    <measurement group_id="O2" value="1.748" lower_limit="1.486" upper_limit="2.010"/>
                    <measurement group_id="O3" value="1.685" lower_limit="1.426" upper_limit="1.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.135</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.504</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.437</ci_lower_limit>
            <ci_upper_limit>0.294</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Proximal Femur BMD, Week 52, ITT Population</title>
        <time_frame>Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Proximal Femur BMD, Week 52, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.809" lower_limit="1.524" upper_limit="2.093"/>
                    <measurement group_id="O2" value="2.130" lower_limit="1.845" upper_limit="2.415"/>
                    <measurement group_id="O3" value="2.099" lower_limit="1.815" upper_limit="2.383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.321</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.724</ci_lower_limit>
            <ci_upper_limit>0.082</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.290</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.692</ci_lower_limit>
            <ci_upper_limit>0.112</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Total Proximal Femur BMD, Week 52 / Endpoint, ITT Population</title>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Total Proximal Femur BMD, Week 52 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.785" lower_limit="1.508" upper_limit="2.062"/>
                    <measurement group_id="O2" value="2.073" lower_limit="1.793" upper_limit="2.352"/>
                    <measurement group_id="O3" value="2.075" lower_limit="1.799" upper_limit="2.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.288</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.682</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.290</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.681</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Total Proximal Femur BMD, Week 104, ITT Population</title>
        <time_frame>Week 104</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Total Proximal Femur BMD, Week 104, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.177" lower_limit="1.805" upper_limit="2.549"/>
                    <measurement group_id="O2" value="2.821" lower_limit="2.438" upper_limit="3.204"/>
                    <measurement group_id="O3" value="2.764" lower_limit="2.389" upper_limit="3.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.644</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.179</ci_lower_limit>
            <ci_upper_limit>-0.110</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.587</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.116</ci_lower_limit>
            <ci_upper_limit>-0.059</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Total Proximal Femur BMD, Week 104 / Endpoint, ITT Population</title>
        <time_frame>Week 104 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Total Proximal Femur BMD, Week 104 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.028" lower_limit="1.671" upper_limit="2.386"/>
                    <measurement group_id="O2" value="2.551" lower_limit="2.190" upper_limit="2.912"/>
                    <measurement group_id="O3" value="2.496" lower_limit="2.139" upper_limit="2.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.522</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.030</ci_lower_limit>
            <ci_upper_limit>-0.014</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.468</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.973</ci_lower_limit>
            <ci_upper_limit>0.037</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck BMD, Week 26, ITT Population</title>
        <time_frame>Week 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck BMD, Week 26, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.120" lower_limit="0.792" upper_limit="1.447"/>
                    <measurement group_id="O2" value="1.385" lower_limit="1.053" upper_limit="1.716"/>
                    <measurement group_id="O3" value="1.246" lower_limit="0.920" upper_limit="1.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.265</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.731</ci_lower_limit>
            <ci_upper_limit>0.201</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.126</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.588</ci_lower_limit>
            <ci_upper_limit>0.336</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck BMD, Week 52, ITT Population</title>
        <time_frame>Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck BMD, Week 52, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.155" lower_limit="0.814" upper_limit="1.496"/>
                    <measurement group_id="O2" value="1.482" lower_limit="1.140" upper_limit="1.825"/>
                    <measurement group_id="O3" value="1.717" lower_limit="1.376" upper_limit="2.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.328</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.811</ci_lower_limit>
            <ci_upper_limit>0.156</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.563</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.045</ci_lower_limit>
            <ci_upper_limit>-0.080</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck BMD, Week 52 / Endpoint, ITT Population</title>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>ITT Population. LOCF at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck BMD, Week 52 / Endpoint, ITT Population</title>
          <population>ITT Population. LOCF at Week 52.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.180" lower_limit="0.853" upper_limit="1.507"/>
                    <measurement group_id="O2" value="1.507" lower_limit="1.177" upper_limit="1.838"/>
                    <measurement group_id="O3" value="1.717" lower_limit="1.390" upper_limit="2.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.327</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.793</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.537</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.000</ci_lower_limit>
            <ci_upper_limit>-0.074</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck BMD, Week 104, ITT Population</title>
        <time_frame>Week 104</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck BMD, Week 104, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.530" lower_limit="1.105" upper_limit="1.955"/>
                    <measurement group_id="O2" value="2.108" lower_limit="1.670" upper_limit="2.545"/>
                    <measurement group_id="O3" value="2.328" lower_limit="1.899" upper_limit="2.758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.578</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.189</ci_lower_limit>
            <ci_upper_limit>0.032</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.799</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.403</ci_lower_limit>
            <ci_upper_limit>-0.194</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck BMD, Week 104 / Endpoint, ITT Population</title>
        <time_frame>Week 104 / Endpoint</time_frame>
        <population>ITT Population. LOCF at Week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck BMD, Week 104 / Endpoint, ITT Population</title>
          <population>ITT Population. LOCF at Week 104.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.431" lower_limit="1.028" upper_limit="1.834"/>
                    <measurement group_id="O2" value="1.986" lower_limit="1.579" upper_limit="2.393"/>
                    <measurement group_id="O3" value="2.047" lower_limit="1.644" upper_limit="2.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.555</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.128</ci_lower_limit>
            <ci_upper_limit>0.018</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.616</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.185</ci_lower_limit>
            <ci_upper_limit>-0.046</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Greater Trochanter BMD, Week 26, ITT Population</title>
        <time_frame>Week 26</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Greater Trochanter BMD, Week 26, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="267"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.900" lower_limit="1.470" upper_limit="2.329"/>
                    <measurement group_id="O2" value="2.148" lower_limit="1.713" upper_limit="2.583"/>
                    <measurement group_id="O3" value="2.164" lower_limit="1.736" upper_limit="2.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.249</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.860</ci_lower_limit>
            <ci_upper_limit>0.363</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.265</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.871</ci_lower_limit>
            <ci_upper_limit>0.342</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Greater Trochanter BMD, Week 52, ITT Population</title>
        <time_frame>Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Greater Trochanter BMD, Week 52, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.297" lower_limit="1.854" upper_limit="2.740"/>
                    <measurement group_id="O2" value="2.854" lower_limit="2.409" upper_limit="3.299"/>
                    <measurement group_id="O3" value="2.819" lower_limit="2.376" upper_limit="3.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.557</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.185</ci_lower_limit>
            <ci_upper_limit>0.071</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.522</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.149</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Greater Trochanter BMD, Week 52 / Endpoint</title>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Greater Trochanter BMD, Week 52 / Endpoint</title>
          <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.186" lower_limit="1.746" upper_limit="2.625"/>
                    <measurement group_id="O2" value="2.732" lower_limit="2.288" upper_limit="3.175"/>
                    <measurement group_id="O3" value="2.764" lower_limit="2.326" upper_limit="3.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.546</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.170</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.579</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.199</ci_lower_limit>
            <ci_upper_limit>0.042</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Greater Trochanter BMD, Week 104, ITT Population</title>
        <time_frame>Week 104</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Greater Trochanter BMD, Week 104, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.056" lower_limit="2.523" upper_limit="3.589"/>
                    <measurement group_id="O2" value="4.152" lower_limit="3.603" upper_limit="4.700"/>
                    <measurement group_id="O3" value="4.246" lower_limit="3.707" upper_limit="4.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.095</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.861</ci_lower_limit>
            <ci_upper_limit>-0.329</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.190</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.948</ci_lower_limit>
            <ci_upper_limit>-0.432</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Greater Trochanter BMD, Week 104 / Endpoint</title>
        <time_frame>Week 104 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Greater Trochanter BMD, Week 104 / Endpoint</title>
          <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.772" lower_limit="2.255" upper_limit="3.289"/>
                    <measurement group_id="O2" value="3.691" lower_limit="3.169" upper_limit="4.213"/>
                    <measurement group_id="O3" value="3.828" lower_limit="3.312" upper_limit="4.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.919</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.655</ci_lower_limit>
            <ci_upper_limit>-0.184</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.056</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.787</ci_lower_limit>
            <ci_upper_limit>-0.326</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide/ Creatinine (NTX/Cr), Week 13, ITT Population</title>
        <time_frame>Week 13</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide/ Creatinine (NTX/Cr), Week 13, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="273"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.595" lower_limit="-45.869" upper_limit="-39.320"/>
                    <measurement group_id="O2" value="-46.366" lower_limit="-49.673" upper_limit="-43.059"/>
                    <measurement group_id="O3" value="-45.420" lower_limit="-48.714" upper_limit="-42.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.771</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.885</ci_lower_limit>
            <ci_upper_limit>8.427</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.826</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.819</ci_lower_limit>
            <ci_upper_limit>7.471</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 26, ITT Population</title>
        <time_frame>Week 26</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 26, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.075" lower_limit="-46.449" upper_limit="-39.702"/>
                    <measurement group_id="O2" value="-45.705" lower_limit="-49.119" upper_limit="-42.291"/>
                    <measurement group_id="O3" value="-47.692" lower_limit="-51.062" upper_limit="-44.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.630</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.171</ci_lower_limit>
            <ci_upper_limit>7.431</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.617</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.152</ci_lower_limit>
            <ci_upper_limit>9.386</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 52, ITT Population</title>
        <time_frame>Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 52, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="253"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.223" lower_limit="-45.710" upper_limit="-38.735"/>
                    <measurement group_id="O2" value="-47.263" lower_limit="-50.771" upper_limit="-43.754"/>
                    <measurement group_id="O3" value="-46.863" lower_limit="-50.345" upper_limit="-43.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>5.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.091</ci_lower_limit>
            <ci_upper_limit>9.989</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.640</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.293</ci_lower_limit>
            <ci_upper_limit>9.574</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 52 / Endpoint, ITT Population</title>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 52 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.227" lower_limit="-43.773" upper_limit="-36.680"/>
                    <measurement group_id="O2" value="-46.599" lower_limit="-50.180" upper_limit="-43.017"/>
                    <measurement group_id="O3" value="-44.630" lower_limit="-48.185" upper_limit="-41.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>6.372</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.329</ci_lower_limit>
            <ci_upper_limit>11.414</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.403</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.619</ci_lower_limit>
            <ci_upper_limit>9.425</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 104, ITT Population</title>
        <time_frame>Week 104</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 104, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.188" lower_limit="-53.061" upper_limit="-45.314"/>
                    <measurement group_id="O2" value="-53.927" lower_limit="-57.870" upper_limit="-49.983"/>
                    <measurement group_id="O3" value="-53.186" lower_limit="-57.111" upper_limit="-49.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.739</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.793</ci_lower_limit>
            <ci_upper_limit>10.271</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.999</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.518</ci_lower_limit>
            <ci_upper_limit>9.515</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 104 / Endpoint, ITT Population</title>
        <time_frame>Week 104 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Urine Type-I Collagen N-telopeptide / Creatinine (NTX / Cr), Week 104 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.261" lower_limit="-50.137" upper_limit="-42.386"/>
                    <measurement group_id="O2" value="-51.079" lower_limit="-54.993" upper_limit="-47.165"/>
                    <measurement group_id="O3" value="-49.454" lower_limit="-53.338" upper_limit="-45.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.817</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.693</ci_lower_limit>
            <ci_upper_limit>10.327</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.192</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.295</ci_lower_limit>
            <ci_upper_limit>8.680</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Serum Type-I Collagen C-telopeptide (CTX), Week 13, ITT Population</title>
        <time_frame>Week 13</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Serum Type-I Collagen C-telopeptide (CTX), Week 13, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.331" lower_limit="-45.643" upper_limit="-39.019"/>
                    <measurement group_id="O2" value="-46.781" lower_limit="-50.127" upper_limit="-43.436"/>
                    <measurement group_id="O3" value="-46.054" lower_limit="-49.386" upper_limit="-42.723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.450</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.260</ci_lower_limit>
            <ci_upper_limit>9.160</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>3.723</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.975</ci_lower_limit>
            <ci_upper_limit>8.421</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Serum Type-I Collagen C-telopeptide (CTX), Week 26, ITT Population</title>
        <time_frame>Week 26</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline Serum Type-I Collagen C-telopeptide (CTX), Week 26, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.386" lower_limit="-47.882" upper_limit="-40.889"/>
                    <measurement group_id="O2" value="-49.183" lower_limit="-52.743" upper_limit="-45.623"/>
                    <measurement group_id="O3" value="-49.358" lower_limit="-52.863" upper_limit="-45.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.798</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.195</ci_lower_limit>
            <ci_upper_limit>9.790</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.972</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>9.924</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 52, ITT Population</title>
        <time_frame>Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 52, ITT Population</title>
          <population>ITT Population</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.410" lower_limit="-48.140" upper_limit="-40.680"/>
                    <measurement group_id="O2" value="-49.185" lower_limit="-52.931" upper_limit="-45.440"/>
                    <measurement group_id="O3" value="-50.048" lower_limit="-53.780" upper_limit="-46.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.775</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.514</ci_lower_limit>
            <ci_upper_limit>10.065</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>5.638</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.356</ci_lower_limit>
            <ci_upper_limit>10.920</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 52 / Endpoint, ITT Population</title>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 52 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.172" lower_limit="-45.959" upper_limit="-38.385"/>
                    <measurement group_id="O2" value="-48.724" lower_limit="-52.556" upper_limit="-44.892"/>
                    <measurement group_id="O3" value="-47.703" lower_limit="-51.506" upper_limit="-43.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>6.552</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.162</ci_lower_limit>
            <ci_upper_limit>11.942</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>5.531</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.164</ci_lower_limit>
            <ci_upper_limit>10.897</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 104, ITT Population</title>
        <time_frame>Week 104</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 104, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.155" lower_limit="-48.803" upper_limit="-39.506"/>
                    <measurement group_id="O2" value="-51.985" lower_limit="-56.737" upper_limit="-47.232"/>
                    <measurement group_id="O3" value="-52.538" lower_limit="-57.257" upper_limit="-47.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>7.830</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.175</ci_lower_limit>
            <ci_upper_limit>14.485</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.383</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.757</ci_lower_limit>
            <ci_upper_limit>15.010</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 104 / Endpoint, ITT Population</title>
        <time_frame>Week 104 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Type-I Collagen C-telopeptide (CTX), Week 104 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.451" lower_limit="-45.960" upper_limit="-36.942"/>
                    <measurement group_id="O2" value="-49.253" lower_limit="-53.815" upper_limit="-44.691"/>
                    <measurement group_id="O3" value="-48.752" lower_limit="-53.279" upper_limit="-44.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>7.802</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.385</ci_lower_limit>
            <ci_upper_limit>14.220</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>7.301</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.911</ci_lower_limit>
            <ci_upper_limit>13.690</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 13, ITT Population</title>
        <time_frame>Week 13</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 13, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.386" lower_limit="-25.425" upper_limit="-21.347"/>
                    <measurement group_id="O2" value="-25.141" lower_limit="-27.201" upper_limit="-23.082"/>
                    <measurement group_id="O3" value="-25.191" lower_limit="-27.243" upper_limit="-23.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.755</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.145</ci_lower_limit>
            <ci_upper_limit>4.655</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.805</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.087</ci_lower_limit>
            <ci_upper_limit>4.698</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 26, ITT Population</title>
        <time_frame>Week 26</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 26, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.273" lower_limit="-33.311" upper_limit="-29.236"/>
                    <measurement group_id="O2" value="-33.680" lower_limit="-35.755" upper_limit="-31.606"/>
                    <measurement group_id="O3" value="-32.582" lower_limit="-34.625" upper_limit="-30.540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.407</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.502</ci_lower_limit>
            <ci_upper_limit>5.316</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.309</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.576</ci_lower_limit>
            <ci_upper_limit>4.194</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 52, ITT Population</title>
        <time_frame>Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 52, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.895" lower_limit="-34.132" upper_limit="-29.658"/>
                    <measurement group_id="O2" value="-33.450" lower_limit="-35.696" upper_limit="-31.204"/>
                    <measurement group_id="O3" value="-33.507" lower_limit="-35.745" upper_limit="-31.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.555</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.617</ci_lower_limit>
            <ci_upper_limit>4.727</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.612</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.556</ci_lower_limit>
            <ci_upper_limit>4.779</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 52 / Endpoint, ITT Population</title>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 52 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.367" lower_limit="-33.536" upper_limit="-29.199"/>
                    <measurement group_id="O2" value="-32.802" lower_limit="-34.996" upper_limit="-30.607"/>
                    <measurement group_id="O3" value="-32.829" lower_limit="-35.007" upper_limit="-30.652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.434</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.652</ci_lower_limit>
            <ci_upper_limit>4.521</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.462</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.611</ci_lower_limit>
            <ci_upper_limit>4.535</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 104, ITT Population</title>
        <time_frame>Week 104</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 104, ITT Population</title>
          <population>ITT Population.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.394" lower_limit="-35.969" upper_limit="-30.819"/>
                    <measurement group_id="O2" value="-36.143" lower_limit="-38.776" upper_limit="-33.510"/>
                    <measurement group_id="O3" value="-36.810" lower_limit="-39.424" upper_limit="-34.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.749</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.938</ci_lower_limit>
            <ci_upper_limit>6.436</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.416</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.255</ci_lower_limit>
            <ci_upper_limit>7.087</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus daily treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 104 / Endpoint, ITT Population</title>
        <time_frame>Week 104 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Bone-specific Alkaline Phosphatase, Week 104 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.572" lower_limit="-35.042" upper_limit="-30.103"/>
                    <measurement group_id="O2" value="-34.769" lower_limit="-37.268" upper_limit="-32.271"/>
                    <measurement group_id="O3" value="-34.824" lower_limit="-37.303" upper_limit="-32.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.197</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.318</ci_lower_limit>
            <ci_upper_limit>5.711</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.251</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.248</ci_lower_limit>
            <ci_upper_limit>5.751</ci_upper_limit>
            <estimate_desc>LS Mean Difference is 5 mg daily minus weekly treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One New Fractured Vertebra, Week 52</title>
        <time_frame>Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One New Fractured Vertebra, Week 52</title>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>7.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>8.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One New Fractured Vertebra, Week 52 / Endpoint, ITT Population</title>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One New Fractured Vertebra, Week 52 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>7.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>8.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One New Fractured Vertebra, Week 104, ITT Population</title>
        <time_frame>Week 104</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One New Fractured Vertebra, Week 104, ITT Population</title>
          <population>ITT Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.4505</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>3.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One New Fractured Vertebra, Week 104 / Endpoint, ITT Population</title>
        <time_frame>Week 104 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One New Fractured Vertebra, Week 104 / Endpoint, ITT Population</title>
          <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.4505</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.7719</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>3.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With No New Fractured Vertebra, Week 52</title>
        <time_frame>Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With No New Fractured Vertebra, Week 52</title>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="255"/>
                    <measurement group_id="O3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>7.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>8.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With No New Fractured Vertebra, Week 52 / Endpoint</title>
        <time_frame>Week 52 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With No New Fractured Vertebra, Week 52 / Endpoint</title>
          <population>ITT Population. Last Observation Carried Forward at Week 52.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="259"/>
                    <measurement group_id="O3" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>7.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>8.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With No New Fractured Vertebra, Week 104</title>
        <time_frame>Week 104</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With No New Fractured Vertebra, Week 104</title>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="231"/>
                    <measurement group_id="O3" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.4505</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>3.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With No New Fractured Vertebra, Week 104 / Endpoint</title>
        <time_frame>Week 104 / Endpoint</time_frame>
        <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Before Breakfast</title>
            <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
          </group>
          <group group_id="O2">
            <title>35 mg After Breakfast</title>
            <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
          </group>
          <group group_id="O3">
            <title>35 mg Before Breakfast</title>
            <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With No New Fractured Vertebra, Week 104 / Endpoint</title>
          <population>ITT Population. Last Observation Carried Forward at Week 104.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
                <count group_id="O2" value="265"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                    <measurement group_id="O2" value="263"/>
                    <measurement group_id="O3" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.4505</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To establish the non-inferiority at one-sided α of 2.5% with 90% power, 651 patients (217 per treatment group) was required to complete at least 52 weeks of the study. Adjusting for 20% dropouts, 272 patients per group were required for randomization. This calculation was based on a non-inferiority margin of 1.5%, a true mean difference (μIR - μDR) of 0.25%, and a common standard deviation of the percent change from baseline in lumbar spine BMD at Week 52 of 4.0%.</non_inferiority_desc>
            <p_value>0.7719</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative Risk</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>3.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent Adverse Events (TEAEs) included all Adverse Events (AEs) from the date of first dose of study drug until the patient's Week 52 visit, or until the date the patient exited from the study for those who withdrew prior to the Week 52 visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>5 mg Before Breakfast</title>
          <description>5 mg risedronate immediate-release daily tablet administered at least 30 minutes before breakfast (IRBB)</description>
        </group>
        <group group_id="E2">
          <title>35 mg After Breakfast</title>
          <description>35 mg risedronate delayed-release immediately following breakfast (DRFB), administered once-a-week</description>
        </group>
        <group group_id="E3">
          <title>35 mg Before Breakfast</title>
          <description>35 mg risedronate delayed-release administered at least 30 minutes before breakfast (DRBB), once-a-week</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="307"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hypertensive Heart Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Superventricular Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness Unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Antidiuretic Hormone Abnormality</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular Degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Oedematous Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Sigmoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Exercise Tolerance Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Cholecystitis Infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Mengitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Sinuitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Humerous Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Therapeutic Agent Toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body Mass Index Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Cystoscopy Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>ECG Signs of Myocardial Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Chondrolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Joint Instability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign Breast Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Benign Neoplasm of Adrenal Gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Bladder Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Parkinson's Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety Disorder due to General Medical Condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Emotional Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Stress Urinary Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Urinary Bladder Polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Female Genital Tract Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Vaginal Prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pulmonary Microemboli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Parapsoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="307"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="307"/>
                <counts group_id="E3" subjects_affected="264" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="307"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Supraventricular Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="307"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="307"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism Secondary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hypoparathyroidism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="307"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Abdominal Pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="307"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="307"/>
                <counts group_id="E3" events="23" subjects_affected="20" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="307"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="307"/>
                <counts group_id="E3" events="37" subjects_affected="26" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Colonic Polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="307"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="307"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Dental Caries</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Diarrhea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="307"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="307"/>
                <counts group_id="E3" events="24" subjects_affected="21" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Diverticulum Intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="307"/>
                <counts group_id="E2" events="24" subjects_affected="18" subjects_at_risk="307"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="10" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="307"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="307"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="307"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="307"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Drug Intolerance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholethiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="307"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="307"/>
                <counts group_id="E3" events="24" subjects_affected="21" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="307"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="307"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="307"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="307"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Viral Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="307"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Influenza</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="307"/>
                <counts group_id="E2" events="33" subjects_affected="27" subjects_at_risk="307"/>
                <counts group_id="E3" events="29" subjects_affected="25" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Nasopharyngitis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="307"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="307"/>
                <counts group_id="E3" events="48" subjects_affected="38" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="307"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="307"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="307"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="307"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="307"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="307"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="307"/>
                <counts group_id="E3" events="29" subjects_affected="22" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="307"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="307"/>
                <counts group_id="E3" events="12" subjects_affected="8" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="307"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="307"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Joint Sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Parathyroid Hormone Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="307"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Arthralgia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="33" subjects_at_risk="307"/>
                <counts group_id="E2" events="39" subjects_affected="29" subjects_at_risk="307"/>
                <counts group_id="E3" events="33" subjects_affected="27" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Back Pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="307"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="307"/>
                <counts group_id="E3" events="31" subjects_affected="29" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="307"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="307"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="307"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="307"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="307"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="307"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="307"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="307"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="307"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="307"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="307"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="307"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Sleep Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="307"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="307"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="307"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="307"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="307"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="307"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="307"/>
                <counts group_id="E3" events="22" subjects_affected="21" subjects_at_risk="308"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="307"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="307"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="308"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The findings of the study may be published in a scientific journal or presented at a scientific meeting. Before submitting the results of the study for publication or presentation, the Investigator will allow the sponsor 30 days in which to review and comment on the manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grexan Wulff, Manager Regulatory Affairs</name_or_title>
      <organization>Warner Chilcott</organization>
      <phone>973-442-3376</phone>
      <email>gwulff@wcrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

